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The Anrep effect requires transactivation of the epidermal
growth factor receptor
Marı´a C. Villa-Abrille, Claudia I. Caldiz, Irene L. Ennis, Mariela B. Nolly, Marı´a J. Casarini,
Gladys E. Chiappe de Cingolani, Horacio E. Cingolani and Ne´stor G. Pe´rez
Centro de Investigaciones Cardiovasculares, Facultad de Ciencias Me´dicas, Universidad Nacional de La Plata, Calle 60 y 120, 1900 La Plata, Argentina
Myocardial stretch elicits a biphasic contractile response: the Frank–Starling mechanism
followed by the slow force response (SFR) or Anrep effect. In this study we hypothesized
that the SFR depends on epidermal growth factor receptor (EGFR) transactivation after the
myocardial stretch-induced angiotensin II (Ang II)/endothelin (ET) release. Experiments were
performed in isolated cat papillary muscles stretched from 92 to 98% of the length at which
maximal twitch force was developed (Lmax). The SFR was 123 ± 1% of the immediate rapid
phase (n= 6,P < 0.05) and was blunted by preventing EGFR transactivation with the Src-kinase
inhibitor PP1 (99 ± 2%, n= 4), matrix metalloproteinase inhibitor MMPI (108 ± 4%, n= 11),
the EGFR blocker AG1478 (98 ± 2%, n= 6) or the mitochondrial transition pore blocker
clyclosporine (99 ± 3%, n= 6). Stretch increased ERK1/2 phosphorylation by 196 ± 17% of
control (n= 7, P < 0.05), an effect that was prevented by PP1 (124 ± 22%, n= 7) and AG1478
(131 ± 17%, n= 4). In myocardial slices, Ang II (which enhances ET mRNA) or endothelin-1
(ET-1)-induced increase in O2− production (146 ± 14%, n= 9, and 191 ± 17%, n= 13, of
control, respectively,P < 0.05) was cancelled by AG1478 (94 ± 5%,n= 12, and 98 ± 15%,n= 8,
respectively) or PP1 (100 ± 4%, n= 6, and 99 ± 8%, n= 3, respectively). EGF increased O2−
production by 149 ± 4% of control (n= 9, P < 0.05), an effect cancelled by inhibiting NADPH
oxidase with apocynin (110 ± 6% n= 7), mKATP channels with 5-hydroxydecanoic acid (5-HD;
105 ± 5%, n= 8), the respiratory chain with rotenone (110 ± 7%, n= 7) or the mitochondrial
permeability transition pore with cyclosporine (111 ± 10%, n= 6). EGF increased ERK1/2
phosphorylation (136 ± 8% of control, n= 9, P < 0.05), which was blunted by 5-HD (97 ± 5%,
n= 4), suggesting that ERK1/2 activation is downstream of mitochondrial oxidative stress.
Finally, stretch increased Ser703 Na+/H+ exchanger-1 (NHE-1) phosphorylation by 172 ± 24%
of control (n= 4, P < 0.05), an effect that was cancelled by AG1478 (94 ± 17%, n= 4). In
conclusion, our data show for the first time that EGFR transactivation is crucial in the chain of
events leading to the Anrep effect.
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Introduction
In myocytes, angiotensin II (Ang II) is stored in secretory
vesicles, and its release is triggered by mechanical
stretch (Sadoshima et al. 1993; Leri et al. 1998). The
release of Ang II is sufficient to activate angiotensin
1 (AT1) receptors in an autocrine/paracrine loop that
leads to the release/formation of endothelin (ET) (Ito
et al. 1993; Yamazaki et al. 1996, 1998), the production
of NADPH-dependent mitochondrial reactive oxygen
species (ROS) (Zhou et al. 2006; Caldiz et al. 2007; Zhang
et al. 2009), the activation of redox sensitive kinases,
and the stimulation of the Na+/H+ exchanger-1 (NHE-1)
(Akram et al. 2006; Caldiz et al. 2007). One consequence of
this chain of events appears to be myocardial hypertrophy
(Ennis et al. 2007).
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In concert with the autocrine/paracrine loop, myo-
cardial stretch triggers an increase in cardiac contra-
ctility that develops immediately after the Frank–Starling
mechanism, reaching a maximum after 10 to 15 min. This
is due to an increase in the intracellular calcium trans-
ient, without changes in myofilament calcium sensitivity
(Allen & Kurihara, 1982; Kentish & Wrzosek, 1998; Perez
et al. 2001). This mechanical counterpart of the auto-
crine/paracrine loop is called the slow force response
to stretch (SFR) (Parmley & Chuck, 1973; Calaghan &
White, 2001) or the Anrep effect (von Anrep, 1912;
Sarnoff et al. 1960; Alvarez et al. 1999). The SFR seems
to involve the early intracellular signals that lead to myo-
cardial hypertrophy; in particular, mitochondrial ROS
formation seems to be crucial (Caldiz et al. 2007; Zhang
et al. 2009). Interestingly, recent evidence suggested that
Ang II, the first step in the chain of events that leads to
SFR, requires the transactivation of endothelial growth
factor receptor (EGFR) to induce cardiac hypertrophy
(Kagiyama et al. 2002; Zhai et al. 2006; Szokodi et al.
2008). Furthermore, in neonatal cardiac myocytes, stretch
elicited a mechanism that required EGFR transactivation
to induce the release/formation of ET and, consequently,
the activation of extracellular signal-regulated kinase
(ERK) (Asakura et al. 2002; Duquesnes et al. 2009). We
therefore hypothesised that transactivation of the EGFR
must be critical for the development of the SFR.
This study investigated whether blunting the G protein
coupled receptor (GPCR)-mediated transactivation of
EGFR would block the SFR. A preliminary report of our
data has been presented elsewhere (Perez et al. 2009).
Methods
All procedures followed during this investigation conform
to the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996), to the guidelines
laid down by the Animal Welfare Committee of the
La Plata School of Medicine, and the policies of The
Journal of Physiology (Drummond, 2009). Cats (n = 42,
body weight 3–4 kg) were anaesthetized by intraperitoneal
injection of sodium pentobarbitone (35 mg (kg body
weight)−1). The chests were opened to excise the heart
when deep anaesthesia was reached, verified by the loss of
corneal reflex and appearance of slow deep diaphragmatic
breathing. Animals were provided by a local supplier (San
Cayetano, Monte Grande, Argentina). Each heart was used
to provide papillary muscles as well as cardiac tissue slices.
Isolation of papillary muscles
Papillary muscles from the right ventricle were used
to assess the SFR to stretch as previously described
(Perez et al. 2001). Briefly, the muscles were mounted
in a perfusion chamber placed on the stage of an
inverted microscope (Olympus) and superfused at a
constant rate (5 ml min−1) with a CO2/HCO3−-buffered
solution containing (mmol l−1): NaCl 128.3, KCl 4.5,
CaCl2 1.35, NaHCO3 20.23, MgSO4 1.05, glucose 11.0
and equilibrated with 5% CO2–95% O2 (pH ∼7.40).
The possible participation of catecholamines released by
the nerve endings was prevented by adrenergic receptors
blockade with 1.0 μmol l−1 prazosin plus 1.0 μmol l−1
atenolol. The muscles were paced at 0.2 Hz at a voltage 10%
over threshold maintained at 30◦C, and isometric contra-
ctions were recorded. Cross sectional area (calculated as
0.75 of the product of thickness and width) was used
to normalize force records obtained with a silicon strain
gauge (model AEM 801, Sensonor Technologies, Horten,
Norway). The slack length of each muscle was determined
after mounting, and then the muscles were progressively
stretched to the length at which they developed maximal
twitch force (Lmax). After a few minutes at Lmax, they were
shortened to obtain the 95% of the maximal twitch force
(length that approximated 98% of Lmax and referred to as
L98). Then, the muscles were shortened to 92% of Lmax
(L92) and maintained at this length until the beginning
of the experimental protocol, when they were abruptly
stretched from L92 to L98. The drugs were added to the
perfusate 20 min before stretch, and during this period,
none of them changed the developed force by more than
3% to 4%.
Cardiac tissue slices
Preparation of cardiac slices. Hearts were quickly
removed from previously anaesthetized animals. The
hearts were perfused through the aorta with Krebs–Ringer
buffer pH 7.4 to eliminate the blood, and tissue slices from
the left ventricle (1 × 5 mm) were cut and kept at 4◦C until
assayed. Assay buffer consisted of Krebs-Hepes buffer of
the following composition (in mmol l−1): 118.3 NaCl; 4.7
KCl; 1.8 CaCl2; 1.2 MgSO4; 1.0 K2HPO4; 25 NaHCO3; 11
glucose; 20 Hepes (pH 7.4 after 1.5 h aeration with 95%
O2–5% CO2 at 37◦C). Cardiac tissues were incubated in
assay buffer during 30 min in the presence of different
drugs in a metabolic incubator under 95% O2–5% CO2 at
37◦C before measurements of O2− production.
Measurements of superoxide anions (·O2−) production.
We used lucigenin-enhanced chemiluminescence to
measure O2− production by cat cardiac tissue in
Krebs-Hepes buffer with 5 μmol l−1 lucigenin as described
previously (Caldiz et al. 2007). The chemiluminescence in
arbitrary units (AU) was recorded with a luminometer
(Chameleon; Hidex, Turku, Finland) during 30 s, each
with a 4.5 min interval during 30 min. O2− production was
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normalized to milligrams dry weight tissue per minute.
Control tissue slices without any pharmacological inter-
vention produced low levels of O2− that were only slightly
above background. Although the lucigenin-enhanced
chemiluminescence method does not allow accurate
detection of the basal O2− production (Dikalov et al.
2007), its sensitivity was enough to detect an increase in
O2− production above background after Ang II, ET-1 and
EGF. When necessary, the increase in O2− production was
expressed as a percentage of basal value after 15 min of
each intervention.
Determination of extracellular signal-regulated
protein kinases (ERK1/2) and NHE-1 phosphorylation
Cardiac tissue was homogenized in lysis buffer
(300 mmol l−1 sucrose; 1 mmol l−1 dithiothreitol (DTT);
4 mmol l−1 EGTA, protease inhibitor cocktail (Complete
Mini, Roche); 20 mmol l−1 Tris-HCl, pH 7.4). After
a brief centrifugation the supernatant was kept and
protein concentration determined by the Bradford
method. Samples were denatured and equal amounts
of protein were subjected to PAGE and electro-
transferred to PVDF membranes. Membranes were then
blocked with non-fat dry milk and incubated over-
night with either anti-phospho-ERK1/2 or anti-ERK 2
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). For
NHE-1 phosphorylation determination, samples were
immunoprecipitated using a NHE-1 polyclonal anti-
body (Chemicon, Temecula, CA, USA) and then sub-
jected to PAGE, electrotransferred and incubated with
an anti-14-3-3 binding motif antibody (Cell Signaling
Technology, Inc., Danvers, MA, USA). Previous reports
have shown that the regulatory Ser703 of the NHE-1 lies
within a sequence which creates upon phosphorylation
a binding motif for 14-3-3 proteins (Takahashi et al.
1999; Lehoux et al. 2001). Thus, the anti-P-14-3-3
binding motif antibody when probed with immuno-
precipitated NHE-1 represents a useful tool to estimate
NHE-1 phosphorylation at Ser703 (Snabaitis et al. 2006).
Total ERK-2 and NHE-1 as a loading control were
assayed. Peroxidase-conjugated anti-rabbit or anti-mouse
IgG (Santa Cruz Biotechnology) was used as secondary
antibody and bands were visualized using the ECL-Plus
chemiluminescence detection system (GE Healthcare,
Little Chalfont, UK). Autoradiograms were analysed by
densitometric analysis (Scion Image).
RNA measurements by RT-PCR
Total RNA was isolated from the cardiomyocytes
suspension using the RNeasy kit (Qiagen, Valencia, CA,
USA) according to the manufacturer’s instructions. RNA
(0.8 μg) was reverse-transcribed using the Omniscript RT
kit (Qiagen). A dilution of the resulting cDNA was used
for quantifying the relative content of mRNA by real-time
PCR (iCycler iQ Real-Time PCR Detection System,
Bio-Rad) using appropriate primers and SYBR Green
as a fluorescent probe. The following primers, designed
using Primer3 software, were used: GAPDH: forward
primer 5-GGGTGTGAACCACGAGAAAT-3; reverse
primer 5-CCACAGTCTTCTGAGTGGCA-3; preproET-1:
forward primer 5-CAGACAAAGAACTCCGAGCC-3;
reverse primer 5-GGTCTTGATGCTGTTGCTGA-3. PCR
reactions were performed with TaqDNA polymerase
(Invitrogen). Fluorescence data were acquired at the
end of extension. A melt analysis was run for all of the
products to determine the specificity of the amplification.
The cycle threshold values for each gene were measured
and calculated by computer software (iCycler IQ OSS,
version 3.0a, Bio-Rad). The cycle threshold values for
each gene were normalized by those GAPDH in the same
sample. The primers were designed against the feline
sequences. For each experiment of real-time RT-PCR we
obtained a melting curve of the amplified gene where
it could be appreciated that only a specific product was
amplified in each case with no primer-dimer formation.
Statistics
Results are expressed as means ± S.E.M. Differences
between initial phase and post-stretch records,
comparison of O2− production after 15 min of incubation
with the different drugs and ERK1/2 phosphorylation
under the different conditions were assessed by one-way
ANOVA followed by the Student–Newman–Keuls test.
Two-way ANOVA was used to compare post-stretch data
in the absence and presence of drugs. P < 0.05 was
considered significant.
Results
Probing the intracellular signalling pathway triggered
by myocardial stretch
Figure 1A shows a typical force response to stretch when an
isolated cat papillary muscle is stretched from 92 to 98%
of its maximum length. The result is a biphasic contra-
ctile response: the classical Frank–Starling mechanism
is manifested immediately after stretch, followed by a
gradually developing increase in force, known as the SFR
to stretch or the Anrep effect.
Previous studies from our and other laboratories have
provided evidence that the SFR is the result of an auto-
crine/paracrine loop that begins with the activation of
GPCRs (Ang II and ET) and ends with an increase
in the Ca2+ transient through the Na+/Ca2+ exchanger
(Cingolani et al. 1998; Yamazaki et al. 1998; Alvarez et al.
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1999; Calaghan & White, 2001; Perez et al. 2001, 2003;
Luers et al. 2005). The role of mitochondrial ROS in the
intracellular signalling pathway was also recently described
(Caldiz et al. 2007; Zhang et al. 2009).
In order to probe the connection between EGFR trans-
activation and the SFR, we explored whether inhibiting
EGFR transactivation would affect the SFR of a papillary
muscle. Several mediators are known to be involved in the
transactivation process, but the precise communication
between the GPCR and EGFR is not entirely understood
(Wetzker & Bohmer, 2003). One proposed mediator is
Src tyrosine kinase (Wetzker & Bohmer, 2003); thus, as
a first test of our hypothesis, we inhibited Src kinase
with the specific tyrosine kinase inhibitor PP1. Figure 1C
shows that PP1 (1 μmol l−1) completely cancelled the
SFR to stretch. Another proposed mediator (Krieg et al.
2004; Szokodi et al. 2008) of EGFR transactivation was
heparin-binding EGF (HB-EGF). HB-EGF is generated
through extracellular proteolytic cleavage of proHB-EGF
by the action of a matrix metalloproteinase (MMP).
To test the contribution of this signalling pathway to
the SFR, we inhibited MMP with MMP inhibitor III
(MMPI), which specifically targeted MMPs 1, 2, 3, 7 and
13. MMPI (3 μmol l−1) did not completely eliminate the
SFR, but significantly reduced its magnitude by ∼60%
(Fig. 1B). This provided further support of the notion that
EGFR transactivation was required for a fully developed
SFR.
Finally, we specifically inhibited the EGFR with
AG1478 (1 μmol l−1), which is known to prevent
receptor phosphorylation, and consequently, blocks
receptor activation. Under these conditions, the SFR was
completely abolished (Fig. 1D). The average SFR observed
under the different experimental conditions was expressed
as a percentage of the initial rapid phase (Fig. 1E).
Thus, these three interventions that interfered with
the mechanism of transactivation significantly decreased
the SFR. These results support the hypothesis that EGFR
transactivation plays a role in the development of the SFR
in cat myocardium.
Activation of redox sensitive kinases after myocardial
stretch
We (Cingolani et al. 2005; Caldiz et al. 2007) and others
(Zhang et al. 2009) have previously shown that the SFR
depends on the activation of NHE-1, which is a target of the
redox sensitive kinases, ERK1/2. Others showed that ROS
stimulated NHE-1 through MAPK (Rothstein et al. 2002;
Haworth et al. 2003; Fliegel & Karmazyn, 2004; Akram
et al. 2006), and we recently proposed that stretch induced
the mitochondrial production of ROS (Caldiz et al. 2007).
In this study, muscles were frozen 5 min after myocardial
stretch and processed for kinase detection. We detected
a significant increase in ERK1/2 phosphorylation. This
effect was cancelled by pre-treatment with either AG1478
or PP1 (Fig. 2), two inhibitors of EGFR transactivation
that also blocked the mechanical response. These findings
showed that the prevention of EGFR phosphorylation and
activation is able to cancel both the increase in ERK1/2
phosphorylation and the mechanical response to stretch.
Figure 1. SFR and EGFR transactivation
A, a typical force record from a cat papillary muscle
subjected to an increase in length from 92 to 98% of
Lmax; the biphasic response to stretch can be seen
(vertical dotted lines indicate stretching interval). B–D,
same as A but from muscles pretreated with matrix
metalloproteinase inhibitor (MMPI, B), the Src kinase
inhibitor PP1 (C) or the EGFR blocker AG1478 (D),
interventions that cancel EGFR transactivation. As can
be seen, all these pharmacological interventions
prevented the development of the SFR to stretch.
E, the averaged results obtained under the different
experimental conditions expressed as a percentage of
the initial rapid phase. ∗P < 0.05 control curve vs.
others (2-way ANOVA). §P < 0.05 vs. initial rapid phase
(for the sake of clarity, significance is indicated only for
15 min of stretch).
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Ang II, ET-1, ROS production and transactivation of
the EGFR
We proposed that mitochondrial ROS are a necessary
upstream signal for ERK1/2 activation, NHE-1
phosphorylation, and SFR development. Our proposal
was based on evidence that physiological concentrations of
exogenous Ang II or ET-1 induced a NADPH-dependent
increase in O2− formation, and this could be blunted by
interfering with the mitochondrial ROS source (Caldiz
et al. 2007). Here, we found that either AG1478 or PP1
suppressed Ang II/ET-1-induced O2− formation in cat
myocardial slices (Fig. 3). These results implied that EGFR
transactivation is critical in mediating the Ang II and ET-1
induction of ROS production.
Ang II–ET-1 cross talk
Myocardial stretch causes the release of preformed Ang II
from neonatal (Sadoshima et al. 1993) and adult myo-
cytes (Leri et al. 1998). The effects induced by physio-
logical Ang II concentrations can be blunted by inter-
fering with ET-1, either by blocking the endothelin type-A
(ETA) receptor or by inhibiting the ET conversion enzyme
(Alvarez et al. 1999; Perez et al. 2001; Cingolani et al. 2005,
2006). Furthermore, the presence of prepro-ET, Big ET,
and ET was detected in the cardiomyocytes (Cingolani
et al. 2006). Therefore, myocardial stretch induces Ang II
and/or ET actions.
The mechanism by which Ang II elicited ET
release/formation is not fully known. Based on studies
on B-type natriuretic peptide production in neonates,
Anderson et al. (2004) proposed that stretch induced
ET release through a NADPH-dependent, redox-sensitive
mechanism. Consistent with his proposal, we found that
1 nmol l−1 of Ang II increased the mRNA expression
of ET-1 in cat myocytes (Fig. 4), perhaps reflecting
the replenishment of a released pool and/or increased
ET-1 formation. This effect was inhibited by the AT1
blocker losartan, the NADPH inhibitor apocynin and the
ROS scavenger 2-mercaptopropionyl glycine. The exact
mechanism of the cross talk between Ang II and ET-1 is
out of the scope of this study; however, these findings
showed that the cross talk between Ang II and ET-1 was
sensitive to the redox state in the adult feline heart.
Increased ROS formation by EGF signalling
In order to investigate this mechanism further, we
evaluated whether EGF was able to increase O2− formation
under our experimental conditions. We found that EGF
increased myocardial O2− production in a dose-dependent
manner (Fig. 5). The effect of EGF at 0.1 μg ml−1 was
similar to the increase in O2− production observed
with 1 nmol l−1 ET-1; thus, we decided to use this EGF
concentration in the following experiments. The increase
in O2− production induced by 0.1 μg ml−1 EGF was,
as expected, cancelled by pre-treatment with the EGFR
Figure 2. ERK1/2 phosphorylation after stretch
Five minutes of stretch significantly increased ERK1/2 phosphorylation, kinases upstream NHE-1, that we have
previously shown to play a critical role in SFR development (Caldiz et al. 2007). This effect was blunted either
by EGFR blockade with AG1478 (AG, A) or by Src kinase inhibition with PP1 (B), demonstrating that EGFR
transactivation after stretch is necessary for ERK1/2 phosphorylation. It is important to highlight that either
AG1478 or PP1 alone did not modify basal ERK1/2 phosphorylation (92 ± 4%, n = 4, and 107 ± 8%, n = 4, of
control respectively). ∗P < 0.05 vs. non-stretched control.
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blocker AG1478, but not by the Src kinase inhibitor
PP1 (Fig. 5B), which is upstream of the EGFR trans-
activation pathway (Wetzker & Bohmer, 2003; Krieg
et al. 2004). As reported previously for Ang II/ET-1
(Caldiz et al. 2007), the increase in ROS production
was NADPH dependent, since it was eliminated by
apocynin (Fig. 5B). Furthermore, EGF-induced ROS
production was abrogated by blocking mitochondrial
ATP-sensitive potassium channels (mKATP) with
5-hydroxydecanoic acid (5-HD; a mKATP-specific
blocker) and glybenclamide (a non-selective KATP
blocker), or the mitochondrial respiration inhibitor
rotenone (Fig. 5B). Thus, these data support the notion
that Ang II elicits an increase in mitochondrial ROS
formation through an intracellular signalling pathway that
involves ET and EGFR transactivation.
ERK1/2 phosphorylation by EGF: role of mitochondria
Next, we reasoned that, if Ang II/ET-1 generated the
ROS that activated the ERK1/2 kinases and led to
Figure 3. O2− production after addition of Ang II or ET-1 in
cardiac slices
The increase in O2− production induced either by 1 nmol l−1 Ang II (A)
or 1 nmol l−1 ET-1 (B) was cancelled by AG1478 or PP1. These findings
demonstrate that the well known increase in ROS production after
Ang II/ET-1 treatment requires EGFR transactivation in the
myocardium. ∗P < 0.05 vs. control.
NHE-1 phosphorylation (Rothstein et al. 2002; Haworth
et al. 2003; Fliegel & Karmazyn, 2004; Caldiz et al.
2007), and these effects depended on EGFR trans-
activation, then EGF should be able to induce ERK1/2
phosphorylation. Figure 6 shows that an increase in
ERK1/2 phosphorylation was induced by 0.1 μg ml−1 EGF.
This increase was abolished by AG1478 (not shown),
and also by inhibiting the NADPH oxidase (apocynin),
the mKATP channels (with 5-HD or glybenclamide)
or the mitochondrial respiratory chain (rotenone). This
clearly suggested that mitochondrial ROS formation was
a necessary step upstream of ERK 1/2 phosphorylation.
Role of mitochondrial permeability transition pore
(MPTP) in SFR
Based on the above data, we could conclude that SFR
development depended on EGFR transactivation inducing
the formation of mitochondrial ROS. Transactivation
may induce mitochondrial ROS formation by promoting
the opening of mKATP channels. This would, in turn,
modulate MPTP formation and lead to an increase in O2−
production. If the MPTP were involved in mitochondrial
ROS release, then the prevention of MPTP opening should
prevent ROS formation and thus block the SFR to stretch.
Figure 7 shows that this was indeed the case. Pretreatment
of papillary muscles with the MPTP inhibitor cyclo-
sporine A (0.5 μmol l−1) completely cancelled the SFR.
Figure 4. Ang II–ET-1 crosstalk
Ang II (1 nmol l−1) promoted a significant increase in preproET-1
mRNA expression detected by real-time RT-PCR, a result that confirms
the Ang II–ET crosstalk in the cat myocardium. This increase in
preproET-1 mRNA was, as expected, not only cancelled by AT1
receptor blockade with losartan (Los), but also by scavenging ROS with
2-mercaptopropionyl glycine (MPG) or by inhibiting NADPH oxidase
with apocynin (Apo), indicating that NADPH oxidase-mediated ROS
production is a key step to increase ET-1 expression. ∗P < 0.05 vs.
control.
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Figure 5. O2− production after addition of EGF in cardiac slices
Direct activation of the EGFR by EGF significantly enhanced O2− production in a dose-dependent manner (A). We
selected the lower concentration of EGF (0.1 μg ml−1) to perform subsequent experiments because it increased
O2− production in a similar magnitude to 1 nmol l−1 ET-1 (see Fig. 3). As expected, the 0.1 μg ml−1 EGF effect
was blunted by specific EGFR blockade with AG1478 (AG) but not by Src kinase inhibition with PP1 (B) since the
latter is located upstream of EGFR. The EGF-induced increase in O2− production was also prevented by NADPH
oxidase inhibition with apocynin (Apo), by two different mitochondrial ATP-sensitive K+ channel (mKATP) blockers
(5-hydroxydecanoate (5-HD) and glybenclamide (Gly)), and also by the respiratory chain inhibitor rotenone (Rot).
These data support the hypothesis that EGF is a necessary mediator in the stretch-induced mitochondrial ROS
production. ∗ and # indicate P < 0.05 vs. control and 0.1 μg ml−1 EGF respectively.
In addition, cyclosporine prevented the EGF-mediated
increase in O2− production (Fig. 7).
The changes in O2− production were measured by
the lucigenin method; thus, we could not determine
whether the activation of kinases and NHE was mediated
by O2− or H2O2. O2− is very unstable, and it is
rapidly converted by superoxide dismutase (SOD) into
H2O2, a more stable, membrane-permeant ROS that
is widely recognized as a signalling molecule. In the
myocardium, dismutation is performed by a membrane
bound extracellular SOD, a cytoplasmic CuZn SOD, and
a mitochondrial Mn SOD. Therefore, the O2− detected
in cardiac slices might be easily converted into H2O2 at
different cellular locations, upstream or downstream of
the mitochondria. Furthermore, Sabri et al. (1998) and
Rothstein et al. (2002) demonstrated that H2O2 was the
intracellular signal that led to the activation of kinases
that phosphorylated the NHE; furthermore, we have pre-
viously shown that promoting an increased conversion of
O2− into H2O2 led to an enhanced SFR (Caldiz et al. 2007).
These results suggested that H2O2 plays an important role
in the development of the SFR or Anrep effect.
NHE-1 phosphorylation
We (Cingolani et al. 1998; Alvarez et al. 1999; Cingolani
et al. 2005) and others (Calaghan & White, 2001; Luers
et al. 2005) have previously demonstrated that the SFR
was cancelled by NHE-1 inhibitors in different species. The
underlying mechanism was the prevention of the NHE-1
activation-induced increase in intracellular Na+ that
would favour intracellular Ca2+ accumulation through the
Figure 6. ERK1/2 phosphorylation after EGF stimulation
EGF significantly increased ERK1/2 phosphorylation, an effect that was
cancelled by 5-HD, glybenclamide (Gly), rotenone (Rot) or apocynin
(Apo). These results further support the notion that mitochondrial ROS
formation is a necessary upstream step to ERK 1/2 phosphorylation.
∗P < 0.05 vs. control.
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Na+/Ca2+ exchanger (Alvarez et al. 1999; Perez et al. 2001,
2003).
Previous reports (Takahashi et al. 1999; Lehoux et al.
2001; Snabaitis et al. 2006) have shown that Ser703 in
the regulatory carboxyl-tail of NHE-1 creates a binding
motif for 14-3-3 proteins upon phosphorylation by
ERK1/2-p90RSK cascade. We estimated the levels of
NHE-1 phosphorylation at Ser703 with a phospho-Ser
14-3-3 binding motif antibody. Figure 8 shows that
phosphorylation in the 14-3-3 binding motif was increased
with myocardial stretch and the increase was prevented
with AG1478. A limitation of our study is that NHE-1
Figure 7. Role of MPTP in the development of the SFR
MPTP inhibition with cyclosporine cancelled the SFR as shown in A
(representative force record) and B (averaged results expressed as a
percentage of the initial rapid phase). Interestingly, cyclosporine also
cancelled the increase in O2− production induced by 0.1 ng ml−1 EGF.
These results suggest a role for MPTP in the development of the Anrep
effect, probably by permitting the release of mitochondrial ROS. For
the sake of comparison a control SFR already presented in Fig. 1E and
a control EGF-promoted O2− production shown in Fig. 5B were also
included in panels B and C. ∗P < 0.05 vs. control (panel B) or vs. EGF
(panel C).
phosphorylation was estimated by an antibody that
specifically detects P-Ser703; potential changes in the
phosphorylation state of other sites of the exchanger,
which might contribute to the SFR, were not explored
in the present work.
Our results support the notion that GPCR
induced-EGFR transactivation plays a role in the chain
of events that lead to NHE-1 phosphorylation and SFR
development.
Discussion
In 1912, von Anrep (von Anrep, 1912) observed that, when
aortic resistance was elevated, ventricular volume first
increased and then declined towards its original value.
An influence appeared to operate soon after the initial
dilatation, which caused the heart to return toward the
control volume. Rosenblueth et al. (1959) made similar
observations in the right ventricle. Sarnoff et al. (1960)
coined the expression ‘homeometric autoregulation’ to
denote a mechanism that countered changes in myocardial
length (Frank–Starling mechanism or heterometric auto-
regulation) and originated in the same myocardium.
Figure 8. Stretch-induced NHE-1 phosphorylation
Five minutes of stretch significantly increased NHE-1 phosphorylation
at Ser703 estimated by a phospho-Ser 14-3-3 binding motif antibody.
This effect was cancelled when the EGFR was blocked by AG 1478
(AG). These results support a role of the EGFR transactivation in
the chain of events leading to NHE-1 phosphorylation and SFR
development. It is important to highlight that AG1478 alone did not
modify basal NHE-1 phosphorylation (93 ± 4% of control, n = 4).
∗P < 0.05 vs. control.
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In 1973, Parmley and Chuck reproduced this
phenomenon in myocardial strips (Parmley & Chuck,
1973). They excluded the possibility that changes in
coronary blood flow could be responsible for the
phenomenon (Monroe et al. 1972). Subsequently, other
investigators (Allen & Kurihara, 1982; Kentish & Wrzosek,
1998; Alvarez et al. 1999; Calaghan & White, 2001; Perez
et al. 2001) provided further insight on the mechanisms
involved in the increase in myocardial force triggered by
myocardial stretching.
In our laboratory, the finding that myocardial stretch
induced alkalization in cat papillary muscles bathed
in bicarbonate-free medium indicated that NHE-1 was
activated (Cingolani et al. 1998). We also found that
NHE-1 activation was suppressed by blockade of either
AT1 or ETA receptors (Cingolani et al. 2005). This
led us to propose that Ang II/ET were autocrine or
paracrine mediators of this phenomenon (Cingolani
et al. 1998). The NHE-1-mediated increase in intra-
cellular Na+ concentration (Perez et al. 2003), the increase
in action potential duration (Zhou et al. 2006), and
probably a redox-sensitive phosphorylation of the cardiac
Na+/Ca2+ exchanger (Eigel et al. 2004) appeared to be
factors that contribute to the increase in contractility
that follows myocardial stretch. Interestingly, in previous
works, we were able to eliminate changes in pHi as a
possible contributor to the SFR (Alvarez et al. 1999;
Perez et al. 2001), because under physiological conditions
(bicarbonate buffer), the enhanced activity of NHE-1
was not accompanied by significant changes in pHi. This
was due to the simultaneous Ang II activation of the
Na+-independent Cl−/HCO3− anion exchanger (Alvarez
et al. 2001; Cingolani et al. 2003). Several studies have
shown that Ang II/ET increase ROS formation through a
NADPH oxidase/mitochondrial action (Zorov et al. 2000;
Seshiah et al. 2002; Cingolani et al. 2006). We recently
proposed that the same signalling pathway plays a pivotal
role in the genesis of the SFR to stretch (Caldiz et al. 2007)
by activation of redox-sensitive kinases upstream of the
NHE-1.
It has recently been established that transactivation of
the EGFR is the primary mechanism that underlies GPCR
agonist activation of ERK1/2 and its downstream intra-
cellular pathways (Lemarie et al. 2008). Furthermore, myo-
cardial stretch (Anderson et al. 2004; Duquesnes et al.
2009), myocardial hypertrophy (Kagiyama et al. 2002),
and ET-1 signalling (Asakura et al. 2002) have been shown
to involve EGFR transactivation. The present study has
provided the first evidence for the crucial role of EGFR
transactivation in the development of the SFR. Based on
our previous and present findings, we propose that the
hypothetical signalling pathway schematised in Fig. 9 is
the mechanism that underlies SFR development. We have
recently proposed a crucial role of mitochondrial ROS
in promoting the development of the SFR (Caldiz et al.
2007); and the present work provides conclusive evidence
that EGFR transactivation is a key step in the induction of
mitochondrial ROS formation.
In addition, our experimental data clearly indicated that
ROS signalling takes place downstream of mitochondrial
stimulation, and upstream of ERK1/2 stimulation.
However, this study did not rule out any additional
effects that ROS might have had on one or several
other reactions in the chain of events described in Fig. 9.
Figure 9. Scheme of the proposed mechanism leading to the SFR
Stretch and/or angiotensin II (Ang II) through AT1 receptor stimulation triggers the release/formation of endothelin
(ET). NADPH oxidase-generated reactive oxygen species (ROS) probably play a significant role in this step of the
signalling cascade. ET activates the ETA receptor and induces epidermal growth factor receptor (EGFR) trans-
activation. The communication between the ETA receptor and the EGFR involves matrix metalloprotease (MMP)
activation and possibly the ROS-sensitive Src kinase. EGFR activation triggers an intracellular signalling pathway that
leads to mKATP channel opening increasing ROS production and release through the mitochondrial permeability
transition pore (MPTP). This causes ERK1/2 activation and NHE-1 phosphorylation at Ser703, increasing NHE-1
activity and intracellular Na+ concentration that favours intracellular Ca2+ accumulation through the Na+/Ca2+
exchanger (NCX). The increase in ROS production can also contribute to the increase in intracellular Ca2+ through
a direct stimulatory effect on the NCX (Eigel et al. 2004) and by increasing action potential duration (Zhou et al.
2006).
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For example, others have implicated ROS mediation
in signalling pathways that lead to stretch-induced ET
release (Anderson et al. 2004), kinase-dependent NHE-1
activation (Rothstein et al. 2002; Seshiah et al. 2002;
Caldiz et al. 2007), MMP activation (Wetzker & Bohmer,
2003), and EGFR phosphorylation by inactivation of a
phosphatase (Salmeen et al. 2003; van Montfort et al.
2003). ROS were also proposed to mediate the opening of
mKATP channels through a NADPH oxidase-dependent
mechanism that subsequently induced mitochondrial
ROS release (Brandes, 2005; Kimura et al. 2005). It is
also important to highlight that NADPH oxidase is now
recognized to exist in different subcellular localisations
that enable the targeting of specific compartments. In this
context, it was difficult to determine, with the methods
used in this study, the precise steps in which ROS were
critically important in the chain of events triggered by
stretch. However, we presented evidence that EGFR trans-
activation is a crucial step in the ROS generation that leads
to the Anrep effect.
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